Skip to main content
OpenTrials
Completed

NCT Number: NCT02451904

Severe and Cerebral Malaria Investigated Through Host Metabolomics

* The aim is to describe disease mechanisms of severe and cerebral malaria and identify new targets for adjunctive therapies. * Despite treatment between 10-30% of patients with severe malaria die. * Metabolic acidosis and cerebral malaria are major complications associated with mortality across all age groups. Still, their underlying pathogenesis remains incompletely understood. * Using a metabolomics approach, this study aims to characterise the spectrum of acids accumulating during acidosis, and investigate patterns of metabolic dysregulation associated with coma and seizures.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chittagong Medical College Hospital (CMCH)

Chittagong, Bangladesh

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Severe/Cerebral Malaria:

  • Any P. falciparum parasitaemia detected by asexual stages on a peripheral blood-slide or a positive rapid diagnostic test in combination with one or more Modified WHO Criteria for Severe Malaria (Hien et al, 1996)
  • < 24 hours after treatment commencement with either parenteral artemisinin or quinine
  • Age > 12 years
  • Full informed written consent obtained

Uncomplicated malaria:

  • Any level of Plasmodium parasitaemia, detected by asexual stages on a peripheral blood-slide or a positive rapid diagnostic test without any of the complications of severe malaria stated above.
  • Age > 12 years
  • Full informed written consent obtained

Sepsis:

  • Clinical signs of infection in combination with any two of the following signs:
  • Heart rate > 90 beats per minute;
  • Respiratory rate > 20 breaths per minute, a PaCO2 of < 32 mmHg, or the use of mechanical ventilation for an acute respiratory process;
  • Tympanic temperature > 38°C or < 36 °C;
  • White-cell count of > 12x109/L or < 4x109/L, or a differential count showing 10% immature neutrophils ;
  • Negative peripheral blood slide for any stages of malaria parasites or a negative rapid diagnostic test for falciparum and vivax malaria
  • [As bacterial culture is not routinely available at the study site, positivity of cultures is not required]
  • Age > 12 years
  • Full informed written consent obtained

Acidosis:

  • Clinical suspicion of metabolic acidosis in combination with any of the following:
  • Peripheral venous bicarbonate < 15 mmol/L
  • Peripheral venous base excess < -3 mmol/L
  • Negative peripheral blood slide for any stages of malaria parasites or a negative rapid diagnostic test for falciparum and vivax malaria; and not meeting any of the inclusion criteria for sepsis as stated above.
  • Age > 12 years
  • Full informed written consent obtained

Encephalitis:

  • GCS < 11/15
  • Documented fever > 38°C
  • Onset of symptoms < 2 weeks, with an indication a lumbar puncture as part of the diagnostic work up
  • Negative peripheral blood slide for any stages of malaria parasites or a negative rapid diagnostic test for falciparum and vivax malaria
  • Age > 12 years
  • Full informed written consent obtained

Healthy volunteers:

  • No chronic or acute disease
  • No fever in the past 2 weeks
  • Age > 16 years
  • Full informed written consent obtained

Exclusion criteria

  • Known pre-existing chronic medical conditions including advanced hepatic disease.

Treatment and study plan

observation

Other

Primary outcomes

  1. Characterisation of patterns of metabolic dysregulation in severe malaria

    Time frame: 4-6 weeks

    Interrelationship between disturbances in metabolic pathways associated with acidosis and cerebral malaria

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Collaborators

  • Chittagong Medical College and Hospital

Registry information

Official study title

Microvascular and Metabolic Dysregulation in the Pathogenesis of Severe and Cerebral Malaria Investigated Through Host Metabolomics

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
May 22, 2015
Registry last updated
Jun 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.